NCLEX-style practice question
A nurse is reviewing the FDA approval process for a new drug intended to treat a rare, life-threatening disease for which no other therapy exists. Which statement best reflects how the FDA weighs the drug's risks and benefits?
- The drug must show no adverse effects before it can be approved for any population.
- Risks that would be unacceptable for a non-life-threatening condition may be acceptable when the benefits outweigh them for this condition.
- Approval requires three separate clinical trials regardless of how rare the disease is.
- Risk is evaluated only by the drug manufacturer, and the FDA does not review the data.
Show answer and rationale
Correct answer: B. Risks that would be unacceptable for a non-life-threatening condition may be acceptable when the benefits outweigh them for this condition.
The FDA analyzes the target condition and available treatments, so for a life-threatening disease with no alternatives, higher risks may be acceptable when benefits outweigh them. The FDA reviews the manufacturer's data independently, so the option stating the manufacturer alone evaluates risk is wrong. Requiring zero adverse effects is unrealistic because all drugs carry risks.
Adapted from Open RN Nursing Pharmacology, Chippewa Valley Technical College, CC BY 4.0.
Category: Pharmacological and Parenteral Therapies / Pharmacological Therapies